Hormonal therapy for women with stage IA endometrial cancer of all grades

Jeong Yeol Park, Dae Yeon Kim, Tae Jin Kim, Jae-Weon Kim, Jong Hyeok Kim, Yong Man Kim, Young Tak Kim, Duk Soo Bae, Joo Hyun Nam

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

OBJECTIVE:: To estimate the oncologic and pregnancy outcomes after oral progestin treatment of women of reproductive age with stage IA endometrial adenocarcinoma with stage IA, grade 1 differentiation with superficial myometrial invasion or stage IA, grade 2-3 differentiation with or without superficial myometrial invasion. METHODS:: Medical records of 48 women (age 40 years or younger) with endometrioid adenocarcinoma of the uterus who met inclusion criteria and were treated conservatively with oral progestin were reviewed. Follow-up was performed primarily with imaging techniques followed by endometrial biopsy when indicated. RESULTS:: The median age was 30 years (range, 23-40 years). Fourteen patients (29.2%) received daily oral megestrol acetate (median dose 160 mg per day, range 40-240 mg per day) and 34 (70.8%) received daily oral medroxyprogesterone acetate (median dose 500 mg per day, range 80-1,000 mg per day). Complete responses were observed for 37 patients (77.1%) after the median treatment duration of 10 months (range 3-20 months). Complete response rates were 76.5%, 73.9%, and 87.5% for patients with stage IA, grade 2-3 without myometrial invasion (n=17), for patients with stage IA, grade 1 with superficial myometrial invasion (n=23), and for patients with stage IA, grade 2-3 with superficial myometrial invasion (n=8), respectively (P=.731). Recurrence rates for 37 patients who achieved complete response after a median follow-up time of 48 months (range 7-136 months) were 23.1%, 47.1%, and 71.4%, respectively (P=.104). None experienced disease progression or died of the disease. Nine patients gave birth to 10 healthy newborns. CONCLUSION:: Progestin treatment appears to be reasonably effective for patients with stage IA, grade 2-3 differentiation without myometrial invasion and patients with stage IA grade 1 differentiation with superficial myometrial invasion.

Original languageEnglish
Pages (from-to)7-14
Number of pages8
JournalObstetrics and Gynecology
Volume122
Issue number1
DOIs
StatePublished - 1 Jan 2013

Fingerprint

Endometrial Neoplasms
Progestins
Therapeutics
Megestrol Acetate
Endometrioid Carcinoma
Medroxyprogesterone Acetate
Pregnancy Outcome
Uterus
Medical Records
Disease Progression
Adenocarcinoma
Parturition
Newborn Infant
Biopsy
Recurrence

Cite this

Park, J. Y., Kim, D. Y., Kim, T. J., Kim, J-W., Kim, J. H., Kim, Y. M., ... Nam, J. H. (2013). Hormonal therapy for women with stage IA endometrial cancer of all grades. Obstetrics and Gynecology, 122(1), 7-14. https://doi.org/10.1097/AOG.0b013e3182964ce3
Park, Jeong Yeol ; Kim, Dae Yeon ; Kim, Tae Jin ; Kim, Jae-Weon ; Kim, Jong Hyeok ; Kim, Yong Man ; Kim, Young Tak ; Bae, Duk Soo ; Nam, Joo Hyun. / Hormonal therapy for women with stage IA endometrial cancer of all grades. In: Obstetrics and Gynecology. 2013 ; Vol. 122, No. 1. pp. 7-14.
@article{859f72a162dd4403a21cfcca9dda0f94,
title = "Hormonal therapy for women with stage IA endometrial cancer of all grades",
abstract = "OBJECTIVE:: To estimate the oncologic and pregnancy outcomes after oral progestin treatment of women of reproductive age with stage IA endometrial adenocarcinoma with stage IA, grade 1 differentiation with superficial myometrial invasion or stage IA, grade 2-3 differentiation with or without superficial myometrial invasion. METHODS:: Medical records of 48 women (age 40 years or younger) with endometrioid adenocarcinoma of the uterus who met inclusion criteria and were treated conservatively with oral progestin were reviewed. Follow-up was performed primarily with imaging techniques followed by endometrial biopsy when indicated. RESULTS:: The median age was 30 years (range, 23-40 years). Fourteen patients (29.2{\%}) received daily oral megestrol acetate (median dose 160 mg per day, range 40-240 mg per day) and 34 (70.8{\%}) received daily oral medroxyprogesterone acetate (median dose 500 mg per day, range 80-1,000 mg per day). Complete responses were observed for 37 patients (77.1{\%}) after the median treatment duration of 10 months (range 3-20 months). Complete response rates were 76.5{\%}, 73.9{\%}, and 87.5{\%} for patients with stage IA, grade 2-3 without myometrial invasion (n=17), for patients with stage IA, grade 1 with superficial myometrial invasion (n=23), and for patients with stage IA, grade 2-3 with superficial myometrial invasion (n=8), respectively (P=.731). Recurrence rates for 37 patients who achieved complete response after a median follow-up time of 48 months (range 7-136 months) were 23.1{\%}, 47.1{\%}, and 71.4{\%}, respectively (P=.104). None experienced disease progression or died of the disease. Nine patients gave birth to 10 healthy newborns. CONCLUSION:: Progestin treatment appears to be reasonably effective for patients with stage IA, grade 2-3 differentiation without myometrial invasion and patients with stage IA grade 1 differentiation with superficial myometrial invasion.",
author = "Park, {Jeong Yeol} and Kim, {Dae Yeon} and Kim, {Tae Jin} and Jae-Weon Kim and Kim, {Jong Hyeok} and Kim, {Yong Man} and Kim, {Young Tak} and Bae, {Duk Soo} and Nam, {Joo Hyun}",
year = "2013",
month = "1",
day = "1",
doi = "10.1097/AOG.0b013e3182964ce3",
language = "English",
volume = "122",
pages = "7--14",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "1",

}

Park, JY, Kim, DY, Kim, TJ, Kim, J-W, Kim, JH, Kim, YM, Kim, YT, Bae, DS & Nam, JH 2013, 'Hormonal therapy for women with stage IA endometrial cancer of all grades', Obstetrics and Gynecology, vol. 122, no. 1, pp. 7-14. https://doi.org/10.1097/AOG.0b013e3182964ce3

Hormonal therapy for women with stage IA endometrial cancer of all grades. / Park, Jeong Yeol; Kim, Dae Yeon; Kim, Tae Jin; Kim, Jae-Weon; Kim, Jong Hyeok; Kim, Yong Man; Kim, Young Tak; Bae, Duk Soo; Nam, Joo Hyun.

In: Obstetrics and Gynecology, Vol. 122, No. 1, 01.01.2013, p. 7-14.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hormonal therapy for women with stage IA endometrial cancer of all grades

AU - Park, Jeong Yeol

AU - Kim, Dae Yeon

AU - Kim, Tae Jin

AU - Kim, Jae-Weon

AU - Kim, Jong Hyeok

AU - Kim, Yong Man

AU - Kim, Young Tak

AU - Bae, Duk Soo

AU - Nam, Joo Hyun

PY - 2013/1/1

Y1 - 2013/1/1

N2 - OBJECTIVE:: To estimate the oncologic and pregnancy outcomes after oral progestin treatment of women of reproductive age with stage IA endometrial adenocarcinoma with stage IA, grade 1 differentiation with superficial myometrial invasion or stage IA, grade 2-3 differentiation with or without superficial myometrial invasion. METHODS:: Medical records of 48 women (age 40 years or younger) with endometrioid adenocarcinoma of the uterus who met inclusion criteria and were treated conservatively with oral progestin were reviewed. Follow-up was performed primarily with imaging techniques followed by endometrial biopsy when indicated. RESULTS:: The median age was 30 years (range, 23-40 years). Fourteen patients (29.2%) received daily oral megestrol acetate (median dose 160 mg per day, range 40-240 mg per day) and 34 (70.8%) received daily oral medroxyprogesterone acetate (median dose 500 mg per day, range 80-1,000 mg per day). Complete responses were observed for 37 patients (77.1%) after the median treatment duration of 10 months (range 3-20 months). Complete response rates were 76.5%, 73.9%, and 87.5% for patients with stage IA, grade 2-3 without myometrial invasion (n=17), for patients with stage IA, grade 1 with superficial myometrial invasion (n=23), and for patients with stage IA, grade 2-3 with superficial myometrial invasion (n=8), respectively (P=.731). Recurrence rates for 37 patients who achieved complete response after a median follow-up time of 48 months (range 7-136 months) were 23.1%, 47.1%, and 71.4%, respectively (P=.104). None experienced disease progression or died of the disease. Nine patients gave birth to 10 healthy newborns. CONCLUSION:: Progestin treatment appears to be reasonably effective for patients with stage IA, grade 2-3 differentiation without myometrial invasion and patients with stage IA grade 1 differentiation with superficial myometrial invasion.

AB - OBJECTIVE:: To estimate the oncologic and pregnancy outcomes after oral progestin treatment of women of reproductive age with stage IA endometrial adenocarcinoma with stage IA, grade 1 differentiation with superficial myometrial invasion or stage IA, grade 2-3 differentiation with or without superficial myometrial invasion. METHODS:: Medical records of 48 women (age 40 years or younger) with endometrioid adenocarcinoma of the uterus who met inclusion criteria and were treated conservatively with oral progestin were reviewed. Follow-up was performed primarily with imaging techniques followed by endometrial biopsy when indicated. RESULTS:: The median age was 30 years (range, 23-40 years). Fourteen patients (29.2%) received daily oral megestrol acetate (median dose 160 mg per day, range 40-240 mg per day) and 34 (70.8%) received daily oral medroxyprogesterone acetate (median dose 500 mg per day, range 80-1,000 mg per day). Complete responses were observed for 37 patients (77.1%) after the median treatment duration of 10 months (range 3-20 months). Complete response rates were 76.5%, 73.9%, and 87.5% for patients with stage IA, grade 2-3 without myometrial invasion (n=17), for patients with stage IA, grade 1 with superficial myometrial invasion (n=23), and for patients with stage IA, grade 2-3 with superficial myometrial invasion (n=8), respectively (P=.731). Recurrence rates for 37 patients who achieved complete response after a median follow-up time of 48 months (range 7-136 months) were 23.1%, 47.1%, and 71.4%, respectively (P=.104). None experienced disease progression or died of the disease. Nine patients gave birth to 10 healthy newborns. CONCLUSION:: Progestin treatment appears to be reasonably effective for patients with stage IA, grade 2-3 differentiation without myometrial invasion and patients with stage IA grade 1 differentiation with superficial myometrial invasion.

UR - http://www.scopus.com/inward/record.url?scp=84880570508&partnerID=8YFLogxK

U2 - 10.1097/AOG.0b013e3182964ce3

DO - 10.1097/AOG.0b013e3182964ce3

M3 - Article

C2 - 23743459

AN - SCOPUS:84880570508

VL - 122

SP - 7

EP - 14

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 1

ER -